Takeda col­lab­o­rates with Noile-Im­mune Biotech

BioSpectrum (Asia) - - Company News -

Takeda Phar­ma­ceu­ti­cal Com­pany Limited and Noile-Im­mune Biotech Inc. have en­tered into a col­lab­o­ra­tion to de­velop next gen­er­a­tion chimeric anti­gen re­cep­tor T-cell ther­apy (CAR-T). Noile-Im­mune has ex­clu­sive li­cence for a next gen­er­a­tion CAR-T cell ther­apy de­vel­oped at Ya­m­aguchi Univer­sity. The CAR-T ther­apy pro­duces cy­tokines, chemokines and other mol­e­cules, and is ex­pected to po­ten­tially in­flu­ence or al­ter the tu­mor mi­croen­vi­ron­ment of solid tu­mor tis­sues. The two com­pa­nies in­tend to use this tech­nol­ogy to dis­cover and de­velop new CAR-T im­munother­a­pies, with the aim of treat­ing a broad range of can­cers. In ad­di­tion to pro­vid­ing re­sources re­quired for im­ple­men­ta­tion, Takeda will make a tech­nol­ogy ac­cess pay­ment to NoileIm­mune Biotech as well as an eq­uity in­vest­ment.

Takeda will have ex­clu­sive op­tions to ob­tain li­cens­ing rights for the devel­op­ment and com­mer­cial­iza­tion of Noile-Im­mune’s pipe­line and prod­ucts re­sult­ing from this part­ner­ship on pre-agreed terms. Takeda signed the agree­ment with Noile-Im­mune through its wholly-owned sub­sidiary, Mil­len­nium Phar­ma­ceu­ti­cals, Inc.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.